Edouard Fu, PhD student at the Department of Clinical Epidemiology at the LUMC, uses big data to study the effectiveness and safety of kidney, diabetes and heart failure treatments. With a Rubicon grant from NWO, Edouard will conduct further research at Harvard Medical School over the next two years.
In the first round of Rubicon 2021, a total of 24 newly graduated scientists were selected to conduct research abroad at prestigious institutions such as Oxford and Harvard.
Wonder drugs for diabetics?
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new group of medications used for treating patients with type 2 diabetes, kidney disease, or heart failure. The potential impact of this novel medication class is enormous: type 2 diabetes currently affects more than 400 million people worldwide, whereas heart failure is the leading cause of hospitalizations in the Western world.
Considered a breakthrough in the treatment of diabetes and heart failure, Edouard Fu – however – highlights that initial clinical trials on the effectiveness and safety of SGLT2 inhibitors do not portray the whole picture quite yet. “These trials included very selective patient populations and their study size and duration is often not sufficient to investigate rare – but potentially serious safety outcomes. By applying cutting-edge statistical methods to big data of more than 200 million patients, we will be able to investigate the effectiveness and safety of these drugs in patients with diabetes and heart failure in a real-life setting.”
In 2018, Prasanna Iyengar was awarded a Marie Skłodowska-Curie – Postdoctoral Fellowship (MSCA-IF) to implement a research project on bladder cancer at Leiden University Medical Center (LUMC) in The Netherlands. This two-year fellowship allowed Prasanna to pursue an independent line of research as a senior postdoc, thereby elucidating mechanisms of bladder cancer metastasis as well as further developing his career track.
Leiden2022 marks what the City of Leiden has achieved in science till date and how it wishes to move forward to contribute to challenges of various kinds. The LUMC is one of many organizations showcasing science in practice with interactive events for a variety of target groups. Like with all Leiden based companies, Leiden2022 offers the LUMC the opportunity to show its societal and academic value on an international stage, strengthening its international position, as well as explore possibilities for new international collaborations to contribute to global healthcare challenges even more comprehensively. The Global Impact in Health symposium on May 30th, 2022, part of the LSH week, aims to stimulate just that by bringing together healthcare experts from all over the world working on a broad range of important health(care) related research and projects. Here’s a few things you can expect.
LUMC Global has set out to stimulate international connections in (bio)medical research and education to contribute to global healthcare. Setting up several PhD projects has been one of the key elements in doing this and we’re very proud we’ve been able to set up as many as eight different PhD projects. We are now looking for a Global PhD candidate in Obstetrics in a collaborative projects with Karolinska Institutet, Sweden and UZ Leuven, Belgium.